Perspective Therapeutics Engages Investors in December Conferences
SEATTLE, November 20, 2025 – Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leader in radiopharmaceutical development, is set to engage its investors through a series of conferences this December. The company, which is dedicated to pioneering advanced treatments for various cancers, will have senior leaders participating in discussions and one-on-one meetings aimed at fostering stronger relationships with investors.
Upcoming Conference Details
Piper Sandler & Co. 37th Annual Healthcare Conference
Date: Tuesday, December 2, 2025
Time: 1:00 - 1:25 p.m. ET
Location: New York, NY
Evercore 8th Annual Healthcare Conference
Date: Wednesday, December 3, 2025
Time: 3:00 - 3:20 p.m. ET
Location: Miami, FL
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is dedicated to transforming the landscape of cancer treatment through its innovative radiopharmaceuticals. Leveraging proprietary technology, the company employs the alpha-emitting isotope 212Pb, allowing for targeted radiation therapy aimed directly at cancer cells. This unique approach enhances treatment precision and minimizes collateral damage to healthy tissues, offering hope to patients facing various types of cancer.
Innovative Therapeutic and Diagnostic Strategies
The company is actively engaged in developing complementary imaging diagnostics that incorporate the same targeting moieties used in its therapeutic products. This dual approach – known as “theranostics” – empowers healthcare professionals to visualize specific tumors and tailor treatments to maximize efficacy while reducing side effects.
Currently, Perspective is running Phase 1/2a imaging and therapy trials for its key programs, including treatments for neuroendocrine tumors (VMT-?-NET), melanoma (VMT01), and solid tumors (PSV359) in the United States.
Expanding Operations and Compliance
In addition to clinical advancements, Perspective Therapeutics is expanding its network of drug product candidate finishing facilities. This growth is facilitated by the company’s proprietary 212Pb generator, ensuring the timely availability of patient-ready products for both clinical trials and future commercial operations. The commitment to creating accessible treatment options is paramount as the company strengthens its operational capabilities.
For More Information
For further insights into the company's innovative approaches and ongoing developments, interested parties can visit www.perspectivetherapeutics.com.
Investor Relations
For media inquiries or investor relations, please contact:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
Frequently Asked Questions
What is the focus of the upcoming conferences for Perspective Therapeutics?
The conferences will offer opportunities for the company’s leadership to connect with investors and discuss the latest advancements in cancer treatments.
What innovative technology does Perspective Therapeutics utilize?
Perspective uses the alpha-emitting isotope 212Pb to target cancer cells directly, minimizing exposure to healthy tissues.
What are the key programs under development at Perspective Therapeutics?
The company's key programs include treatments for neuroendocrine tumors, melanoma, and solid tumors, all currently in Phase 1/2a trials.
How does Perspective Therapeutics ensure patient-ready products?
Through its proprietary generator and expanding operational facilities, the company aims to provide timely access to its drug product candidates for clinical trials.
How can investors learn more about Perspective Therapeutics?
Investors can visit the company's official website for updates, or contact their investor relations team for specific inquiries.
